Health Care • Biotechnology: Pharmaceutical Preparations
$160.79 ▼ -0.31
(-0.19%)
MKT CAP: $307.40B • VOL: 3.15M
52W L $123 52W H $170
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$135
MEDIAN
$180
MEAN
$183
HIGH
$219
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE NVS TAPE
NVS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $194.56 | $184.91 | 2025-02-14 | $146.32 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $202.60 | $189.73 | 2025-02-06 | $151.14 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $183.30 | $176.87 | 2025-01-29 | $154.36 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $164.01 | — | 2025-01-17 | $157.57 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $141.50 | $152.75 | 2025-01-09 | $143.10 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $191.34 | $167.22 | 2024-12-18 | $139.89 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $155.97 | $162.40 | 2024-12-04 | $149.53 | -4.3% | 48% | C |